+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Cervical Cancer Screening Market, Forecast 2022-2027, Industry Trends, Share, Growth, Outlooks, Impact of COVID-19, Company Analysis

  • PDF Icon

    Report

  • 205 Pages
  • March 2022
  • Region: Europe
  • Renub Research
  • ID: 5562700
Europe Cervical Cancer Screening Market is expected to be valued at US$ 10.7 Billion in 2027. Cervical cancer originates in the cervix cells, which is the lower section of the uterus that attaches to the vaginal canal. Cervical cancer is now one of the most common malignancies in women and one of the most typical causes of cancer death in Europe. As a result, cervical cancer screening is an essential aspect of a woman's routine health and can aid in cervical cancer prevention. Furthermore, many women are now opting for a cervical cancer screening test due to increased awareness. The European government is also playing a critical role by organizing free medical camps, health reimbursement, and awareness activities.



Europe Cervical Cancer Screening Market is estimated to expand with a CAGR of 3.3% during 2021-2027:


The European Cervical Cancer Screening Market has grown in recent years due to an increase in the number of patients diagnosed with cervical cancer and increased awareness about cervical cancer screening programs. In addition, the market is being boosted by the increased demand for technologically sophisticated diagnostic treatments for detecting cervical and vaginal malignancies. Furthermore, the growing demand for better cancer diagnostics and recent advancements in cancer diagnosis and therapy, novel specific antigen identification, and insights into cancer's genetic underpinning have all aided the market's growth. The expanding older population will also add fuel to this business, as their desire for further cancer assays and tests will increase, leading to future market growth in Europe.

Pap Smear Test and HPV DNA Test Population & Market:


Because of the high incidence and death rate of cervical cancer in Europe, there is a huge demand for unique and reliable early detection and therapeutic screening. Surprisingly, there are excellent screening procedures for detecting precancerous cervix lesions. The publisher examined the Europe Cervical Cancer Screening Market in the analysis, including Pap Smear Test and HPV DNA Test Population and Market. Cervical cancer screening tests are divided into Pap tests and HPV testing.

Cells from the cervix are removed, stained, and evaluated for abnormalities during a Pap test. Pap tests are frequently used in women to confirm cervical cancer or to search for changes in cells that could lead to cervical cancer in the future. As a result of the failure of cytology-based screening programs in Europe, alternative approaches such as HPV testing have emerged.

HPV infection is determined in HPV test cells collected from the cervix. HPV tests are being used to extend screening intervals and boost coverage in high-risk populations, in addition to their excellent sensitivity. Furthermore, the demand expansion is projected to be aided by breakthrough testing technologies and services that increase screening rates.

By Country - Europe Cervical Cancer Test Market & Population Share Analysis:


The Europe Cervical Cancer Test Market & Population Share Analysis has been done for the United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, and the Netherlands in our report. According to our research, Germany, the United Kingdom, and France are the top three nations in the European region performing very well in the Cervical Cancer Screening Market. The market in the nations mentioned above is likely to dominate, owing to raising awareness of cervical cancer among women and the availability of high-quality healthcare facilities. Furthermore, the market is expected to develop at a faster rate due to rising healthcare costs, government legislation, and healthcare institute attempts to raise awareness about cervical cancer.

Impacts of COVID-19 on Europe's Cervical Cancer Screening Industry:


The abrupt emergence of the COVID-19 pandemic initiated strict lockdown measures across Europe, causing Cervical Cancer Screening to be disrupted. Due to the coronavirus pandemic, cervical cancer screening in European countries has decreased to deficient levels. In the aftermath of COVID-19, most non-urgent cervical cancer appointments were canceled. However, with social distancing and vaccination programs in the European region, the market returned to normal. In 2021, the Europe Cervical Cancer Screening Market was valued at US$ 8.8 Billion, according to the publisher.

This report titled Europe Cervical Cancer Screening Market & Forecast, By Test Population and Market (Pap smear and HPV DNA), Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands) provides a complete analysis of Europe Cervical Cancer Screening Industry.

Cervical Cancer Diagnostics Market has been covered from 2 viewpoints:


1. Pap Smear Tests Market
2. HPV DNA Tests Market

Cervical Cancer Test Population has been covered from 2 viewpoints:


1. Pap Smear Test Population
2. HPV DNA Test Population

All the 9 Countries Studied in the Report are as Follows


1. United Kingdom
2. France
3. German
4. Ital
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherlands
4. Pharmaceuticals
5. Textiles
6. Others

All the key players have been covered 3 Viewpoints


  • Business Overviews
  • Recent Development
  • Sales Analysis

Company Analysis


1. Cargill Inc
2. Ingredion Inc
3. Archer Daniels Midland Company
4. Tate and Lyle, Atlia Group
5. Tereos Group
6. Atlia Group
7. Sudzucker AG
8. Global Bio-Chem Technology Group Company Limited
Frequently Asked Questions about the Europe Cervical Cancer Screening Market

What is the estimated value of the Europe Cervical Cancer Screening Market?

The Europe Cervical Cancer Screening Market was estimated to be valued at $8.8 Billion in 2021.

What is the growth rate of the Europe Cervical Cancer Screening Market?

The growth rate of the Europe Cervical Cancer Screening Market is 3.3%, with an estimated value of $10.7 Billion by 2027.

What is the forecasted size of the Europe Cervical Cancer Screening Market?

The Europe Cervical Cancer Screening Market is estimated to be worth $10.7 Billion by 2027.

Table of Contents

Table of Contents:
1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Europe Cervical Cancer Test (Screening) Analysis
5.1 Europe Cervical Cancer Test Population
5.1.1 Pap smear Test Population
5.1.2 HPV DNA Test Population
5.2 Europe Cervical Cancer Test (Screening) Market
5.2.1 Pap Smear Test Market
5.2.2 HPV DNA Test Market
6. Countries - Europe Cervical Cancer Test Market & Population Share Analysis
6.1 Europe Cervical Cancer Test Population Share
6.1.1 Pap Smear Population
6.1.2 HPV DNA Population
6.2 Europe Cervical Cancer Market Share
6.2.1 Pap Smear Market
6.2.2 HPV DNA Market
7. United Kingdom - Cervical Cancer Test Analysis
7.1 Population - Cervical Cancer Test (Screening)
7.1.1 Pap smear Test Population
7.1.2 HPV DNA Test Population
7.2 Market - Cervical Cancer Test (Screening)
7.2.1 Pap smear Test Market
7.2.2 HPV DNA Test Market
8. France - Cervical Cancer Test Analysis
8.1 Population - Cervical Cancer Test (Screening)
8.1.1 Pap smear Test Population
8.1.2 HPV DNA Test Population
8.2 Market - Cervical Cancer Test (Screening)
8.2.1 Pap Smear Test Market
8.2.2 HPV DNA Test Market
9. Germany - Cervical Cancer Test Analysis
9.1 Population - Cervical Cancer Test (Screening)
9.1.1 Pap smear Test Population
9.1.2 HPV DNA Test Population
9.2 Market - Cervical Cancer Test (Screening)
9.2.1 Pap Smear Test Market
9.2.2 HPV DNA Test Market
10. Italy - Cervical Cancer Test Analysis
10.1 Population - Cervical Cancer Test (Screening)
10.1.1 Pap smear Test Population
10.1.2 HPV DNA Test Population
10.2 Market - Cervical Cancer Test (Screening)
10.2.1 Pap Smear Test Market
10.2.2 HPV DNA Test Market
11. Spain - Cervical Cancer Test Analysis
11.1 Population - Cervical Cancer Test (Screening)
11.1.1 Pap smear Test Population
11.1.2 HPV DNA Test Population
11.2 Market - Cervical Cancer Test (Screening)
11.2.1 Pap Smear Test Market
11.2.2 HPV DNA Test Market
12. Sweden - Cervical Cancer Test Analysis
12.1 Population - Cervical Cancer Test (Screening)
12.1.1 Pap smear Test Population
12.1.2 HPV DNA Test Population
12.2 Market - Cervical Cancer Test (Screening)
12.2.1 Pap Smear Test Market
12.2.2 HPV DNA Test Market
13. Switzerland - Cervical Cancer Test Analysis
13.1 Population - Cervical Cancer Test (Screening)
13.1.1 Pap smear Test Population
13.1.2 HPV DNA Test Population
13.2 Market - Cervical Cancer Test (Screening)
13.2.1 Pap Smear Test Market
13.2.2 HPV DNA Test Market
14. Norway - Cervical Cancer Test Analysis
14.1 Population - Cervical Cancer Test (Screening)
14.1.1 Pap smear Test Population
14.1.2 HPV DNA Test Population
14.2 Market - Cervical Cancer Test (Screening)
14.2.1 Pap Smear Test Market
14.2.2 HPV DNA Test Market
15. Netherlands - Cervical Cancer Test Analysis
15.1 Population - Cervical Cancer Test (Screening)
15.1.1 Pap smear Test Population
15.1.2 HPV DNA Test Population
15.2 Market - Cervical Cancer Test (Screening)
15.2.1 Pap Smear Test Market
15.2.2 HPV DNA Test Market
List Of Figures:
Figure 01: Europe - Cervical Cancer Test (Screening) Population Volume (Million), 2017 - 2021
Figure 02: Europe - Forecast for Cervical Cancer Test (Screening) Population Volume (Million), 2022 - 2027
Figure 03: Europe - Pap Smear Test (Screening) Population Volume (Million), 2017 - 2021
Figure 04: Europe - Forecast for Pap Smear Test (Screening) Population Volume (Million), 2022 - 2027
Figure 05: Europe - HPV DNA Test (Screening) Population Volume (Million), 2017 - 2021
Figure 06: Europe - Forecast for HPV DNA Test (Screening) Population Volume (Million), 2022 - 2027
Figure 07: Europe - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 08: Europe - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 09: Europe - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 10: Europe - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 11: United Kingdom - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 12: United Kingdom - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 13: United Kingdom - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 14: United Kingdom - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 15: United Kingdom - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 16: United Kingdom - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 17: United Kingdom - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 18: United Kingdom - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 19: France - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 20: France - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 21: France - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 22: France - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 23: France - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 24: France - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 25: France - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 26: France - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 27: Germany - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 28: Germany - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 29: Germany - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 30: Germany - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 31: Germany - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 32: Germany - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 33: Germany - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 34: Germany - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 35: Italy - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 36: Italy - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 37: Italy - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 38: Italy - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 39: Italy - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 40: Italy - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 41: Italy - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 42: Italy - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 43: Spain - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 44: Spain - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 45: Spain - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 46: Spain - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 47: Spain - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 48: Spain - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 49: Spain - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 50: Spain - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 51: Sweden - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 52: Sweden - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 53: Sweden - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 54: Sweden - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 55: Sweden - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 56: Sweden - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 57: Sweden - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 58: Sweden - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 59: Switzerland - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 60: Switzerland - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 61: Switzerland - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 62: Switzerland - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 63: Switzerland - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 64: Switzerland - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 65: Switzerland - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 66: Switzerland - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 67: Norway - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 68: Norway - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 69: Norway - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 70: Norway - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 71: Norway - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 72: Norway - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 73: Norway - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 74: Norway - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
Figure 75: Netherlands - Pap Smear Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 76: Netherlands - Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 77: Netherlands - HPV DNA Test (Screening) Population Volume (Thousand), 2017 - 2021
Figure 78: Netherlands - Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2022 - 2027
Figure 79: Netherlands - Pap Smear Test (Screening) Market (Million US$), 2017 - 2021
Figure 80: Netherlands - Forecast for Pap Smear Test (Screening) Market (Million US$), 2022 - 2027
Figure 81: Netherlands - HPV DNA Test (Screening) Market (Million US$), 2017 - 2021
Figure 82: Netherlands - Forecast for HPV DNA Test (Screening) Market (Million US$), 2022 - 2027
List Of Tables:
Table 01: Europe - Pap Smear Test (Screening) Population Volume Share by Country (Percent), 2017 - 2021
Table 02: Europe - Forecast for Pap Smear Test (Screening) Population Volume Share by Country (Percent), 2022 - 2027
Table 03: Europe - HPV DNA Test (Screening) Population Volume Share by Country (Percent), 2017 - 2021
Table 04: Europe - Forecast for HPV DNA Test (Screening) Population Volume Share by Country (Percent), 2022 - 2027
Table 05: Europe - Pap Smear Test (Screening) Market Share by Country (Percent), 2017 - 2021
Table 06: Europe - Forecast for Pap Smear Test (Screening) Market Share by Country (Percent), 2022 - 2027
Table 07: Europe - HPV DNA Test (Screening) Market Share by Country (Percent), 2017 - 2021
Table 08: Europe - Forecast for HPV DNA Test (Screening) Market Share by Country (Percent), 2022 - 2027

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...